We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Merck and Schering-Plough Complete Merger

By HospiMedica International staff writers
Posted on 23 Nov 2009
Following the completion of Merck's merger with Schering-Plough, the company will use the trade name "Merck" in the United States and Canada and elsewhere use the trade name "MSD.”

Following the merger, Merck (Whitehouse Station, NJ, USA) holds a diversified portfolio of prescription medicines, vaccines, and animal and consumer health products. The merged company has approximately 106,000 employees and operates in more than 140 countries around the world, including emerging markets; Merck is expected to reap huge cost savings from the merger by cutting about 15% of the companies' combined workforce. The new organizational structure will take advantage of the combined strengths of Merck and Schering-Plough to create a more customer-focused, innovative, and diversified global health care company positioned to capitalize on opportunities for growth, particularly in emerging markets, biologics, and vaccines. Merck now has five primary divisions: Global Human Health, Animal Health, Consumer Health Care, Merck Research Laboratories, and Merck Manufacturing.

"With our merger now complete, we are ready to deliver on the promise of a new Merck built on a foundation of scientific innovation and dedication to the well-being of patients around the world,” said Richard Clark, chairman, president, and CEO of Merck. "On 'Day One' for the new Merck, we are stronger and better equipped to make a difference in the lives of people globally through our broadened, diversified portfolio of innovative medicines and vaccines, and products for consumer and animal health.”

Under the terms of the merger agreement, valued at U.S. $41.1 billion, Schering-Plough shareholders will receive 0.5767 shares of the newly combined company and $10.50 in cash for each share of Schering-Plough. Each Merck common share will automatically become a common share of the newly combined company.

Related Links:

Merck




Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Electric Cast Saw
CC4 System
New
In-Bed Scale
IBFL500

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024